Revise Phase IV CT Protocol: CDSCO panel tells Zydus Lifesciences on Typhoid Vi Conjugate Vaccine with Yellow Fever Vaccine

Published On 2023-04-15 11:45 GMT | Update On 2024-02-13 18:37 GMT

New Delhi: In response to the drug major Zydus Life Sciences' proposal to conduct Phase IV clinical for Typhoid Vi Conjugate Vaccine I.P.(TCV) with Yellow Fever Vaccine(YFV), the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the firm to revise the Phase IV clinical trial protocol.This came after the firm presented its proposal...

This came after the firm presented its proposal for conducting a Phase IV clinical trial of Typhoid Vi Conjugate Vaccine I.P. (TCV) with Yellow Fever Vaccine (YFV).

TCV Vaccine is an active immunizing agent. It is given to prevent typhoid fever caused by certain bacteria called S. Typhi. It is usually administered at least 2 weeks prior to expected exposure to S. Typhi. Inactivated typhoid vaccine is administered as an injection (shot). It may be given to people 2 years and older. One dose is recommended at least 2 weeks before travel. Repeated doses are recommended every 2 years for people who remain at risk.

Yellow fever vaccine is a vaccine that protects against yellow fever. Yellow fever is a viral infection that occurs in Africa and South America. Most people begin to develop immunity within ten days of vaccination and 99 per cent are protected within one month, and this appears to be lifelong. The vaccine can be used to control outbreaks of disease. It is given either by injection into a muscle or just under the skin.

At the recent SEC meeting for Vaccines held on 23rd of March 2023, the expert panel reviewed the proposal to conduct the Phase IV clinical trial of the Typhoid Vi Conjugate Vaccine I.P. (TCV) with Yellow Fever Vaccine (YFV).

After detailed deliberation, the committee recommended that the firm should revise the Phase IV clinical trial protocol as below:

1. Blood samples should not be withdrawn at visit 2.

2. There should be two reference groups. One group should be administered with the Yellow fever vaccine and other groups should be administered with Typhoid conjugate vaccine.

3. The sample size, primary and secondary endpoints should be defined in accordance with the groups.

Accordingly, the expert panel opined the firm to submit revised clinical trial protocol for further deliberation.

Also Read: CDSCO panel approves Reliance Life Science's Phase III CT Protocol for Tocilizumab

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Revise Phase IV CT Protocol: CDSCO panel tells Zydus Lifesciences on Typhoid Vi Conjugate Vaccine with Yellow Fever Vaccine

Similar News